Aadi Bioscience Informe acción DB:3350 Capitalización de mercado
€48.7m
Finanzas de la empresa + 4 Analistas
Aadi Bioscience, Inc.
Informe acción DB:3350
Capitalización de mercado: €48.7m
Resumen de acción 3350 Aadi Bioscience, Inc, empresa biofarmacéutica, se dedica a desarrollar y comercializar terapias de precisión para cánceres definidos genéticamente con alteraciones en los genes de la vía mTOR.
Recompensas Análisis de riesgos Ver todos los controles de riesgos Competidores de Aadi Bioscience, Inc. Historial de precios y rendimiento
Resumen de todos los máximos históricos, cambios y caídas de precios de Aadi Bioscience Precios históricos de las acciones Precio actual de la acción US$1.91 Máximo en las últimas 52 semanas US$4.82 Mínimo de 52 semanas US$1.18 Beta 0.37 1Cambio en 1 mes 7.91% Variación en 3 meses 52.80% Cambio de 1 año -54.31% 3Variación en 3 años -90.73% Variación en 5 años n/a Variación desde la OPV -90.87%
Noticias y actualizaciones recientes
Aadi Bioscience, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31 Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce Aug 23
Aadi Bioscience Provides PRECISION1 Trial Updates Aug 21
Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.67 loss in 2Q 2023) Aug 08
Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index Jul 03 Ver más actualizaciones
Aadi Bioscience, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31 Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce Aug 23
Aadi Bioscience Provides PRECISION1 Trial Updates Aug 21
Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.67 loss in 2Q 2023) Aug 08
Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index Jul 03
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting May 24
New minor risk - Profitability May 10
Forecast to breakeven in 2026 May 09
First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023) May 08
Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024 Apr 28
Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022) Mar 14
Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024 Mar 07 Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Feb 13
Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations Dec 15
Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.68 loss in 3Q 2022) Nov 10
New minor risk - Market cap size Oct 19
Aadi Bioscience, Inc. Announces Executive Changes Oct 05
Second quarter 2023 earnings released: US$0.67 loss per share (vs US$0.87 loss in 2Q 2022) Aug 10
Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 03
First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022) May 10
High number of new directors Apr 20
High number of new directors Feb 16
High number of new directors Jan 25
Aadi Bioscience, Inc. Announces Management Changes Nov 29
High number of new directors Nov 21
Third quarter 2022 earnings released: US$0.68 loss per share (vs US$9.17 loss in 3Q 2021) Nov 10 Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023
Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium Oct 13
Now 21% undervalued Oct 01
Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.22 loss in 2Q 2021) Aug 11
Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022 Aug 11
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index Jun 26
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications Jun 02
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications Jun 01
Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting May 27
High number of new directors May 26
First quarter 2022 earnings released: US$0.66 loss per share (vs US$0.71 loss in 1Q 2021) May 13 Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders May 10
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services May 05
High number of new directors Apr 29
Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes Apr 01
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 18
Less than half of directors are independent Mar 01
Aadi Bioscience, Inc. Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa Feb 24
Interim Chief Financial Officer Lance Thibault has left the company Dec 01
Aadi Bioscience, Inc. Announces FDA Approval of Its First Product Fyarro™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) Nov 24
No independent directors Sep 01 Rentabilidad de los accionistas 3350 DE Biotechs Mercado DE 7D 8.5% -0.009% -1.2% 1Y -54.3% -17.6% 9.0%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: Los resultados de 3350 fueron inferiores a los de la industria German Biotechs, que obtuvo un rendimiento del -17.6% el año pasado.
Rentabilidad vs. Mercado: 3350 obtuvo unos resultados inferiores a los del mercado German, que fueron del 9% el año pasado.
Volatilidad de los precios Is 3350's price volatile compared to industry and market? 3350 volatility 3350 Average Weekly Movement 6.3% Biotechs Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: 3350 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 3350 ha disminuido de 11% a 6% en el último año.
Acerca de la empresa Fundada Empleados CEO Página web 2007 70 Dave Lennon aadibio.com
Aadi Bioscience, Inc, empresa biofarmacéutica, se dedica a desarrollar y comercializar terapias de precisión para cánceres definidos genéticamente con alteraciones en los genes de la vía mTOR. Su principal candidato a fármaco es FYARRO, una forma de partículas de sirolimus unidas a proteínas para suspensión inyectable destinada al tratamiento de pacientes adultos con PEComa maligno avanzado irresecable o metastásico. La empresa también participa en la evaluación de FYARRO en cánceres, incluidas indicaciones dirigidas a alteraciones genómicas específicas que activan la vía mTOR.
Mostrar más Resumen de fundamentos de Aadi Bioscience, Inc. ¿Cómo se comparan los beneficios e ingresos de Aadi Bioscience con su capitalización de mercado? Estadísticas fundamentales de 3350 Capitalización bursátil €48.75m Beneficios(TTM ) -€58.10m Ingresos (TTM ) €23.61m
2.1x Ratio precio-ventas (PS)
-0.9x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de 3350 Ingresos US$25.07m Coste de los ingresos US$52.61m Beneficio bruto -US$27.54m Otros gastos US$34.15m Beneficios -US$61.69m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -2.50 Margen bruto -109.86% Margen de beneficio neto -246.06% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado 3350 a largo plazo?
Ver rendimiento histórico y comparativa
Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}